Your food choices, activity level, gut health, and blood sugar patterns can influence your bodys natural GLP-1 response
(Left) In liver cells, GLP-1 can mediate cholesterol efflux by acting directly on LXR, or by inducing an increase in ATP-binding cassette transporter A1 (ABCA1) mRNA through Ca2+/calmodulin (CaM)-dependent protein kinase kinase/CAM-dependent protein kinase IV/Prolactin regulatory element binding (CaMKK/CaMKIV/PREB), increasing apolipoprotein AI (apo AI) mRNA and promoter expression, and increasing apo AI secretion, thereby mediating intracellular cholesterol efflux
It is a once-weekly investigational triple agonist designed to activate three metabolic receptor pathways at the same time: GLP-1, GIP, and glucagon
Others need more time at each tier
Specific escalation schedules varied by trial protocol, and the full range of doses studied is described in the published Phase 2 trial data